This biotech company develops novel therapeutics for cancer and autoimmune diseases. Their focus is on creating innovative treatments that improve patient quality of life and survival rates.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for colon diseases often lack precision, leading to suboptimal outcomes and impacting patients' quality of life. Existing therapies may not effectively target the underlying causes of the disease or may have significant side effects.
Solution
Jeevantx is developing next-generation precision medicines aimed at redefining the treatment of colon diseases. The company is pioneering breakthrough therapies designed to transform the lives of patients suffering from these conditions. Jeevantx focuses on creating innovative treatments that offer improved efficacy and reduced side effects compared to existing options.
Target Audience
The primary target audience includes patients suffering from colon diseases and the healthcare providers who treat them.
Features
- Development of novel therapeutics for colon diseases.
- Focus on precision medicine approaches for targeted treatment.
- Aims to improve patient outcomes and quality of life.